Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B100 in patients with T2DM

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

Apolipoprotein B ₁₀₀ (ApoB ₁₀₀) determination is superior to low-density lipoprotein cholesterol (LDL-C) to establish cardiovascular (CV) risk, and does not require prior fasting. ApoB ₁₀₀ is rarely measured alongside standard lipids, which precludes comprehensive assessment of dyslipidemia.

Objectives

To evaluate two simple algorithms for apoB ₁₀₀ as regards their performance, equivalence and discrimination with reference apoB ₁₀₀ laboratory measurement.

Methods

Two apoB ₁₀₀-predicting equations were compared in 87 type 2 diabetes mellitus (T2DM) patients using the Discriminant ratio (DR). Equation 1: apoB ₁₀₀ = 0.65*non-high-density lipoprotein cholesterol + 6.3; and Equation 2: apoB ₁₀₀ = −33.12 + 0.675*LDL-C + 11.95* ln[triglycerides]. The underlying between-subject standard deviation (SD _U) was defined as SD _U = √ (SD ² _B - SD ² _W/2); the within-subject variance (V _w) was calculated for m (2) repeat tests as (V _w) = Σ(x _j -x _i) ²/(m-1)), the within-subject SD (SD _w) being its square root; the DR being the ratio SD _U/SD _W.

Results

All SD _u, SD _w and DR’s values were nearly similar, and the observed differences in discriminatory power between all three determinations, i.e. measured and calculated apoB ₁₀₀ levels, did not reach statistical significance. Measured Pearson’s product-moment correlation coefficients between all apoB ₁₀₀ determinations were very high, respectively at 0.94 (measured vs. equation 1); 0.92 (measured vs. equation 2); and 0.97 ( equation 1 vs. equation 2), each measurement reaching unity after adjustment for attenuation.

Conclusion

Both apoB ₁₀₀ algorithms showed biometrical equivalence, and were as effective in estimating apoB ₁₀₀ from routine lipids. Their use should contribute to better characterize residual cardiometabolic risk linked to the number of atherogenic particles, when direct apoB ₁₀₀ determination is not available.

Related collections

Most cited references 16

Record: found
Abstract: not found
Article: not found

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.

J Brunzell, M. Davidson, C D Furberg … (2008)

0 comments Cited 111 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.

Norm Campbell, André Carpentier, Ehud Ur … (2009)

The present article represents the 2009 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult.

0 comments Cited 88 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes.

J. D. Morris, Benjamin J Levy, P. Hermans … (1999)

Adequate comparisons of the relative performance of different tests of beta-cell function are not available. We compared discrimination of commonly used in vivo tests of beta-cell function across a range of glucose tolerance in seven subjects with normal glucose tolerance (NGT), eight subjects with impaired glucose tolerance (IGT), and nine subjects with type 2 diabetes. In random order, each subject underwent two of each of the following tests: 1) frequently sampled 0.3-g/kg intravenous glucose tolerance test (FSIVGTT) with MinMod analysis; 2) homeostasis model assessment (HOMA) from three samples at 5-min intervals with a model incorporating immunoreactive or specific insulin measurements; and 3) continuous infusion of 180 mg x min(-1) x m(-2) glucose with model assessment (CIGMA) of three samples at 50, 55, and 60 min (1-h CIGMA) and at 110, 115, and 120 min (2-h CIGMA). The discrimination of each test was assessed by the ratio of the within-subject SD to the underlying between-subject SD, the discriminant ratio (DR). The degree to which tests measured the same physiological variable was assessed using Pearson's correlation coefficient adjusted for attenuation due to test imprecision. An unbiased line of equivalence, taking into account the imprecision of both tests, was used to compare results. Beta-cell function assessed from HOMA and beta-cell function assessed from CIGMA (CIGMA%beta) (using immunoreactive insulin) had higher DRs than first-phase intravenous glucose tolerance test-derived incremental insulin peak, area, insulin-to-glucose index, and acute insulin response to glucose from FSIVGTT-MinMod. CIGMA%beta (immunoreactive insulin) had the highest DR. FSIVGTT-derived first-phase insulin response tests correlated only moderately with HOMA and CIGMA. Using specific rather than immunoreactive insulin for HOMA and CIGMA did not improve discriminatory power. Simple tests such as HOMA and CIGMA, using immunoreactive insulin, offer better beta-cell function discrimination across subjects with NGT, IGT, and type 2 diabetes than measurements derived from FSIVGTT first-phase insulin response.

0 comments Cited 42 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (nlm-ta): Cardiovasc Diabetol

Journal ID (iso-abbrev): Cardiovasc Diabetol

Title: Cardiovascular Diabetology

Publisher: BioMed Central

ISSN (Electronic): 1475-2840

Publication date Collection: 2013

Publication date (Electronic): 27 February 2013

Volume: 12

Page: 39

Affiliations

[1 ]Endocrinology & Nutrition, Cliniques universitaires St-Luc and Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium

[2 ]Cardiology Division, Cliniques universitaires St-Luc, and Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium

Article

Publisher ID: 1475-2840-12-39

DOI: 10.1186/1475-2840-12-39

PMC ID: 3601994

PubMed ID: 23446247

SO-VID: a770c31c-0782-47d3-9e43-30e6b5f29f4e

License:

This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.